Wyeth Illegally Blocked Effexor XR Generics: Suit

Law360, New York (July 7, 2011, 4:54 PM EDT) -- Pfizer Inc. unit Wyeth LLC misrepresented clinical data to fraudulently obtain patents in a scheme to block generics from competing with its antidepressant Effexor XR, a retail pharmacy alleged in a class action filed Tuesday in Mississippi federal court.

The pharmacy, Uniondale Chemists Inc., based in New York, says Wyeth engaged in anti-competitive behavior to gain a monopoly on the drug.

The scheme included fraudulently obtaining three patents for extended release formulas of the drug, also known as venlafaxine hydrochloride, in order to maintain a market...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.